It seems that mainstream medicine is keeping close tabs on the Peatarian community. After denying for decades that “primitive” therapies such as aspirin or the mocked “Linus Pauling Protocol” (high-dose intravenous (IV) vitamin C) have any therapeutic effects on cancer, despite reluctantly acknowledging that aspirin may prevent many/most cancers, there have been several studies published in the last year or so that are now making the bold claim that aspirin can (and should) be considered as primary therapy for cancer, or at least for solid tumors. Well, considering my own experiments showing therapeutic effects of aspirin (and B vitamins) in non-solid tumors, I think it is reasonable to claim now that aspirin can (and should) be tried as primary therapy for all types of cancer. In any event, the study below demonstrated striking reduction of tumor growth in an animal model of the invariably lethal Ehrlich ascites carcinoma (EAC) as a result of administering aspirin and/or vitamin C for just 10 days. There were 3 groups – vitamin C, aspirin, and a combination treatment group. The therapeutic effect was the strongest in the combination group, but the monotherapy groups were not far behind. The human equivalent doses were about 550mg/kg vitamin C and 8.5mg/kg daily, with vitamin C administered by injection and aspirin administered orally. There was no toxicity as a result of the administered treatments, which is in direct contradiction to current oncology dogma claiming that any curative treatment for cancer must work, by definition, through a mechanism resulting in the killing of the “mutant” and “alien” cancer cells. Now, a daily dose of 40g-50g vitamin C for a human is a lot and is not feasible to administer orally as most humans cannot absorb more than 2g-3g vitamin C daily via the oral route. That is probably why the study used intraperitoneal route for the vitamin C administration, which mimics well the IV route of the Linus protocol. Not only was this combination treatment highly beneficial for this type of tumor, but (in corroboration) the study cites another one where the same treatment protocol produced better effects for liver cancer than the established “standard of care” treatment. Interestingly, there is already a drug on the market officially approved for cancer treatment in humans, and that drug is just a combination of 5g vitamin C and 50mg vitamin K3 (menadione), administered orally. The drug’s trade name is Apatone, and since vitamin C exhibited a synergistic effects with aspirin in the current study, I suspect augmenting Apatone (maybe call it Apatone+) by adding aspirin to the already approved formulation would further improve its already striking effects on even terminal cancer cases. Also, since Apatone has already demonstrated that 5g of oral vitamin C is enough via oral route, there is no need to go for the massive vitamin C dose administered by injection, as used in this study.
https://pubmed.ncbi.nlm.nih.gov/36809998/
https://pubmed.ncbi.nlm.nih.gov/39012613/
“…A recent study by El Sadda et al. [20] discovered that a combination of ASA and AS was a well-tolerated and effective treatment for hepatocellular carcinoma (HCC) rats, surpassing the effectiveness of doxorubicin treatment; however, testing this combination’s efficacy in treating other types of tumors has still not been investigated. This study investigated the effectiveness of combining ASA and AS compared with treatment with ASA or AS alone in treating Ehrlich solid tumors in mice.”
“…At random, the mice were grouped into eight groups (10 mice each). Four of these groups included healthy mice that were not injected with any solution (Healthy); healthy mice that were treated intraperitoneally with AS (4 g/kg) once daily for 10 consecutive days (AS); healthy mice that were treated by oral gavage with ASA (60 mg/kg) once daily for 10 consecutive days (ASA); and healthy mice that were treated intraperitoneally with AS (4 g/kg) and by oral gavage with ASA (60 mg/kg) once daily for 10 consecutive days (AS+ASA). Four additional groups studied the antitumor effects of AS, ASA, and AS with ASA on tumor-bearing mice. These groups included mice that were injected with EAC cells (subcutaneously with 1×106 tumor cells/mouse into the right thigh of the hind limb) [EAC]; mice bearing solid tumors that were treated intraperitoneally with AS (4 g/kg) once daily for 10 consecutive days, 10 days after solid tumor inoculation (EAC+AS); mice bearing solid tumors that were treated using oral gavage with ASA (60 mg/kg) once daily for 10 consecutive days, 10 days after solid tumor inoculation (EAC+ASA); and mice bearing solid tumors that were treated intraperitoneally with AS (4 g/kg) and by oral gavage with ASA (60 mg/kg) once daily for 10 consecutive days, 10 days after solid tumor inoculation (EAC+AS+ASA).”
“…First, we did not record any toxicity symptoms according to administration of ASA (at a dose of 60 mg/kg) or AS (at a dose of 4 g/kg), or their combination, to healthy mice, and they did not show any significant pathological changes in all the studied parameters. In contrast, they increased antioxidant levels, and decreased MDA and NO levels, suggesting that ASA- and AS-applied doses are well-tolerated for healthy mice. Our results are in unity with Shilpi et al. [18] and Bhattacharyya et al. [27], who reported that AS and ASA are well-tolerated for therapeutic use; however, long-term use or high doses of ASA may cause oxidative stress and result in gastrointestinal erosions and apoptotic lesions [27, 28]. By tumor implantation in the right thigh of a mouse, an increase of 54.58% was recorded in the thigh dimensions in the period from day 11 to day 21 (the day of sacrifice) due to uncontrolled tumor growth. After treatment with ASA, AS, or the combination, we detected a decrease in the thigh dimensions by 2.9%, 20.53%, and 21.8%, and reductions in mean volumes of the separated tumors from mice legs by 40%, 36%, and 46%, respectively, due to tumor shrinking. Undoubtedly, as presented, the regression in solid tumors caused by treatment with the combination was superior. These observations indicate that ASA, AS, or the combination can inhibit tumor growth; however, the combination is more powerful. In 2008, Chen and colleagues found that an intraperitoneal injection of AS (4 g/kg) reduced the size of aggressive glioblastoma, pancreatic, and ovarian tumors in mice by 41–53% [29]. One of the key factors in evaluating a successful compound for fighting cancer and tumors is its ability to prolong lifespan. An increase in lifespan of at least 25% is hypothesized as an effectual antitumor response [30]. Our current research shows that ASA, AS, and their combination may help prolong lifespan and fight cancer. The untreated tumor-bearing mice had an MST of 54 days. By treatment, the MST improved to 81.5, 84, and 93.5 days, with a %ILS of 50.93%, 55.56%, and 73.15%, for ASA, AS, and the combination, respectively.”
